Moderna Omicron vaccine study expands in Bristol to include new booster targeting multiple COVID-19 variants
Volunteers from across Bristol will have the opportunity to take part in one of the world’s first Omicron-specific COVID-19 variant vaccine studies, as biotechnology company Moderna, Inc works with the National Institute for Health Research (NIHR).
The innovative study, which will take place at University Hospitals Bristol and Weston NHS Foundation Trust Clinical Research Facility, will see local participants receive a first or second booster.
The first part of the study looked into the effectiveness of a tweaked Moderna vaccine targeting the Omicron strain, whereas this part of the study will further investigate a bivalent vaccine (one which targets multiple COVID-19 variants) from Moderna.
Half of the volunteers will receive one of Moderna’s Omicron variant vaccines and the other half vaccinated with the commonly used standard Moderna COVID-19 vaccine (Spikevax).
It is the first commercially sponsored Moderna vaccine trial to take place in the UK, and demonstrates the appeal, support and expertise the NIHR and other national research organisations in the UK can provide to the life sciences industry.
This is also one of the first studies globally to be assessing the effectiveness of a fourth COVID-19 dose, and is being led by a team based at St George’s, University of London. The study is open to people who are in good or stable health and have received two or three doses of the COVID-19 vaccine at least 90 days ago.
Dr Rajeka Lazarus, Principal Investigator for the study at University Hospitals Bristol and Weston NHS Foundation Trust:
"We’re reaching out to ask volunteers in Bristol to take part in the latest phase of the Moderna COVID-19 vaccine study. This new phase of the study will further investigate a vaccine which targets multiple COVID-19 variants. By examining the safety and effectiveness of this booster vaccine from Moderna, participants can help in the next step of vaccine research, looking at how we can improve protection against new variants.
"Throughout the pandemic, we’ve been overwhelmed with the generosity of volunteers from the West of England who have come forward to take part in a number of vaccine trials. Without them, the advances we’ve seen in COVID-19 vaccines would not have been possible."
Professor Lucy Chappell, Chief Executive of the National Institute for Health Research, said:
"The last two years have demonstrated the vital importance of international scientific collaboration.
"So it is truly exciting to see the NIHR and Moderna working with research teams across the UK on Moderna's first major UK COVID-19 vaccine study.
"With world-leading researchers, and the unique infrastructure and delivery expertise the NIHR provides, the UK is well-positioned to host exactly these sorts of significant, innovative projects in a post-pandemic world."
Moderna has stated that while a third shot of its original COVID-19 vaccine (also referred to as Spikevax) increased neutralising antibodies against the Omicron variant at the lower half dose (used in the UK rollout), levels declined six months after the booster dose was administered. However, neutralising antibodies remained detectable in all participants.
Stéphane Bancel, Chief Executive Officer of Moderna, said:
"The UK and NIHR have been pioneering in their work to study vaccines and therapeutics throughout the global pandemic and have built-up world class clinical research capabilities.
"This is the first Moderna-sponsored Phase 3 study to be conducted outside of the U.S. with our Omicron-specific booster candidate and we appreciate the collaboration with the NIHR. We thank the clinical trial teams and the participants in the study for helping to advance our understanding of this booster candidate.
"We look forward to continuing our work with the NIHR and engaging further with the life-sciences community in the UK."
Health and Social Care Secretary Sajid Javid said:
"The UK is a world leader when it comes to the research and development of vaccines and medicines, bolstered by our renowned life sciences industry.
"It’s fantastic to see these capabilities being put to good use, with almost 3,000 people expected to take part in this important clinical trial. I want this country to be the best place in the world to launch clinical trials.
"I urge anyone eligible to take part in this vital research and play their part in protecting the country for years to come as we learn to live with COVID-19.”
Those enrolled who have already had a third dose (i.e their booster), must have received an mRNA vaccine (Moderna, Pfizer/BioNTech) as a third dose. Whereas those who have previously received two doses may have received mRNA (Moderna, Pfizer/BioNTech) or non-mRNA (Oxford/AstraZeneca, Janssen) vaccines.
Participants will need to have not tested positive for COVID-19 in the last 90 days, and had their last vaccine at least three months prior to joining the study.
Volunteers from 18 years old and above will be randomly selected to each arm of the study, and blinded to which they receive, with the study looking to evaluate the immune response and safety of the variant jab.
To find out if you are eligible to join the study, visit the study’s website today.
The study will take place at up to 29 research sites across England and Wales and Scotland, with the trial lasting up to 13 months and includes phone calls and visits to the research site.
Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme said:
"The NIHR and research teams across the UK are eager to begin working with Moderna on this cutting edge vaccine study. There are currently a number of variant and multivariant targeting vaccines in development - this was always likely to be one of the next steps in COVID-19 vaccine research, however the emergence of the recent variants has brought forward this process.
"We have seen from the Omicron variant how some existing vaccines may protect less well against new variants, and continued research into which vaccine combinations work best is vital to help us stay protected. I am so grateful to those that have previously volunteered in vaccine studies, and sincerely hope that others will continue to step forward to help us understand these latest bespoke vaccines."
Participants will be monitored throughout the study for any potential side effects and will have to attend to at least seven visits.
